The current directions of searching for antiparasitic drugs
K Dziduch, D Greniuk, M Wujec - Molecules, 2022 - mdpi.com
Parasitic diseases are still a huge problem for mankind. They are becoming the main cause
of chronic diseases in the world. Migration of the population, pollution of the natural …
of chronic diseases in the world. Migration of the population, pollution of the natural …
Synthetic product-based approach toward potential antileishmanial drug development
Leishmaniasis is a parasitic disease and is categorized as a tropically neglected disease
(NTD) with no effective vaccines available. The available chemotherapeutics against …
(NTD) with no effective vaccines available. The available chemotherapeutics against …
Designing, optimization and characterization of trifluralin transfersomal gel to passively target cutaneous leishmaniasis
Herein, Trifluralin (TFL) laden transfersomes (TFS) were investigated against Cutaneous
Leishmaniasis (CL), via localized and targeted dermal delivery of TFL. Designed TFL-TFS …
Leishmaniasis (CL), via localized and targeted dermal delivery of TFL. Designed TFL-TFS …
Need for sustainable approaches in antileishmanial drug discovery
S Hendrickx, G Caljon, L Maes - Parasitology research, 2019 - Springer
Leishmaniasis is a neglected parasitic disease for which the current antileishmania
therapeutics are hampered by drug toxicity, high cost, need for parenteral administration …
therapeutics are hampered by drug toxicity, high cost, need for parenteral administration …
Nanoparticles formulations of artemisinin and derivatives as potential therapeutics for the treatment of cancer, leishmaniasis and malaria
S Alven, BA Aderibigbe - Pharmaceutics, 2020 - mdpi.com
Cancer, malaria, and leishmaniasis remain the deadly diseases around the world although
several strategies of treatment have been developed. However, most of the drugs used to …
several strategies of treatment have been developed. However, most of the drugs used to …
Mannosylated imiquimod-terbinafine co-loaded transethosomes for cutaneous leishmaniasis; assessment of its anti-leishmanial potential, in vivo safety and immune …
Current treatment options for cutaneous leishmaniasis are associated with myriad limiting
factors including low penetration, poor efficacy, and drug toxicities. Herein, we reported …
factors including low penetration, poor efficacy, and drug toxicities. Herein, we reported …
A spotlight on the diagnostic methods of a fatal disease Visceral Leishmaniasis
Leishmania donovani (a causative agent of visceral leishmaniasis) poses a serious health
threat to the human population which is fatal if left untreated. The life cycle of Leishmania …
threat to the human population which is fatal if left untreated. The life cycle of Leishmania …
Genetically modified live attenuated vaccine: a potential strategy to combat visceral leishmaniasis
Visceral leishmaniasis (VL) is caused by a protozoan parasite Leishmania donovani mainly
influencing the population of tropical and subtropical regions across the globe. The arsenal …
influencing the population of tropical and subtropical regions across the globe. The arsenal …
An overview of the fatty acid biosynthesis in the protozoan parasite Leishmania and its relevance as a drug target against leishmaniasis
Leishmaniasis is one of the fast-growing parasitic diseases worldwide. The treatment of this
fatal disease presents a daunting challenge because of its adverse effects, necessity for …
fatal disease presents a daunting challenge because of its adverse effects, necessity for …
[HTML][HTML] Probing O-substituted nifuroxazide analogues against Leishmania: Synthesis, in vitro efficacy, and hit/lead identification
GD Badenhorst, C Kannigadu, J Aucamp… - European Journal of …, 2022 - Elsevier
Leishmaniasis is a neglected tropical disease affecting millions of people worldwide, with
650 000 to 1.1 million new infections reported annually by the World Health Organization …
650 000 to 1.1 million new infections reported annually by the World Health Organization …